<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369265</url>
  </required_header>
  <id_info>
    <org_study_id>10166</org_study_id>
    <nct_id>NCT00369265</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux</brief_title>
  <official_title>A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Institute for Voice and Ear Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Institute for Voice and Ear Research</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Lansoprazole 30mg taken twice daily is
      effective in the treatment of laryngitis due to gastroesophageal reflux.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to study the effect of Lansoprazole 30 mg bid therapy vs. placebo
      in patients who present with symptoms characteristic of reflux laryngitis. The efficacy of
      Lansoprazole 30 mg bid in healing and improving reflux laryngitis will be determined. For the
      purpose of this study, healed reflux laryngitis will be defined as an improvement or
      resolution of arytenoid erythema and improvement in symptoms. Improved reflux laryngitis will
      be defined as improvement in any two of the following areas: arytenoid erythema; voice
      quality as assessed by the patients or health care provider; or, improvement/resolution of
      related symptoms (throat clearing, cough, etc.). The impact of Lansoprazole 30 mg bid therapy
      on quality of life will be evaluated in a preliminary fashion.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Pharmaceutical company purchased by another company and funding was terminated.
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Improvement or Resolution of Arytenoid Erythema</measure>
    <time_frame>6 weeks</time_frame>
    <description>Improvement was measured by score on an arytenoid erythema grading scale assigned by member of research staff and independent observers at 6 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Laryngopharyngeal Reflux</condition>
  <arm_group>
    <arm_group_label>Lansoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lansoprazole 30 mg Twice Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole 30mg twice daily</description>
    <arm_group_label>Lansoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>placebo twice daily</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vocal skills necessary to complete test procedures reliably.

          -  Voice complaints and/or other symptoms suggestive of reflux laryngitis

          -  Signed informed consent

          -  At least 18 years of age.

          -  Complete medical history and physical examination within 30 days prior to initiation
             of the study drug.

          -  Laryngoscopy documenting laryngeal pathology compatible with moderate to severe reflux
             laryngitis (&gt; grade 3 arytenoid erythema) within 30 days of initiation of the study
             drug.

          -  Gastroesophageal reflux confirmed by 24-hour (a minimum of 16 hours required for
             inclusion) pH impedance monitor.

          -  Ambulatory outpatient status.

          -  If female, a negative pregnancy test at the screening visit or either: i) surgically
             sterilized (bilateral tubal ligation or hysterectomy), or ii) at least 1 year
             post-menopausal, or iii) using acceptable methods of contraception in the presence of
             childbearing potential.

        Exclusion Criteria:

          -  Concurrent laryngeal disease, if such disease or its treatment would interfere with
             evaluation of study results. For example, patients with mass lesions such as laryngeal
             cysts or laryngeal carcinoma will be excluded. Patients with acute laryngeal
             infections or acute laryngeal allergies will be excluded until these conditions have
             been resolved; but they may be considered for inclusion thereafter.

          -  Any upper gastroenterological or esophageal surgery except simple over-sewing of a
             perforated ulcer.

          -  Active substance abuse.

          -  Tobacco use.

          -  Known hypersensitivity or allergy to any protein pump inhibitor.

          -  ALT (SGPT) or AST (SGOT) greater than 2 times the upper limit of normal.

          -  Renal impairment (serum creatinine &gt; 2.0 mg/dl).

          -  Any clinically significant, unstable medical condition.

          -  Use of any proton pump inhibitor within 7 days prior to 24-hour pH impedance
             monitoring or baseline strobovideolaryngoscopy, or use of H2 receptor antagonist
             during the 48 hours prior to 24-hour pH impedance monitoring or baseline
             strobovideolaryngoscopy.

          -  Use of an investigational drug or participation in an investigational study, within 30
             days prior to starting study drug.

          -  Previous participation in this study.

          -  Pregnant women.

          -  Women breast feeding infants.

          -  Inability or refusal to follow directions.

          -  Open label sub-study has same inclusion and exclusion criteria, with exception that
             subjects should have: 1) Clinical diagnosis of non-acid reflux, with less than 5
             episodes of proximal acid reflux, and 2) Symptoms and signs consistent with
             gastroesophageal reflux.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert T Sataloff, MD, DMA</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Institute for Voice and Ear Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital, Department of Otolaryngology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Institute for Voice and Ear Research</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University, Van Lawrence Voice Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002 Jun;16(2):274-7.</citation>
    <PMID>12150380</PMID>
  </reference>
  <reference>
    <citation>Belafsky PC, Postma GN, Koufman JA. Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope. 2001 Jun;111(6):979-81.</citation>
    <PMID>11404607</PMID>
  </reference>
  <reference>
    <citation>Bogdasarian RS, Olson NR. Posterior glottic laryngeal stenosis. Otolaryngol Head Neck Surg (1979). 1980 Nov-Dec;88(6):765-72.</citation>
    <PMID>7208045</PMID>
  </reference>
  <reference>
    <citation>Cherry J, Margulies SI. Contact ulcer of the larynx. Laryngoscope. 1968 Nov;78(11):1937-40.</citation>
    <PMID>5722896</PMID>
  </reference>
  <reference>
    <citation>Delahunty JE, Cherry J. Experimentally produced vocal cord granulomas. Laryngoscope. 1968 Nov;78(11):1941-7.</citation>
    <PMID>5722897</PMID>
  </reference>
  <reference>
    <citation>Eherer AJ, Habermann W, Hammer HF, Kiesler K, Friedrich G, Krejs GJ. Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. Scand J Gastroenterol. 2003 May;38(5):462-7.</citation>
    <PMID>12795454</PMID>
  </reference>
  <reference>
    <citation>El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001 Apr;96(4):979-83.</citation>
    <PMID>11316215</PMID>
  </reference>
  <reference>
    <citation>Koufman J, Sataloff RT, Toohill R. Laryngopharyngeal reflux: consensus conference report. J Voice. 1996 Sep;10(3):215-6.</citation>
    <PMID>8865091</PMID>
  </reference>
  <reference>
    <citation>Morrison MD. Is chronic gastroesophageal reflux a causative factor in glottic carcinoma? Otolaryngol Head Neck Surg. 1988 Oct;99(4):370-3.</citation>
    <PMID>3148885</PMID>
  </reference>
  <reference>
    <citation>Noordzij JP, Khidr A, Evans BA, Desper E, Mittal RK, Reibel JF, Levine PA. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope. 2001 Dec;111(12):2147-51.</citation>
    <PMID>11802014</PMID>
  </reference>
  <reference>
    <citation>Vaezi MF, Richter JE, Stasney CR, Spiegel JR, Iannuzzi RA, Crawley JA, Hwang C, Sostek MB, Shaker R. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006 Feb;116(2):254-60.</citation>
    <PMID>16467715</PMID>
  </reference>
  <reference>
    <citation>Wetmore RF. Effects of acid on the larynx of the maturing rabbit and their possible significance to the sudden infant death syndrome. Laryngoscope. 1993 Nov;103(11 Pt 1):1242-54. Review.</citation>
    <PMID>8231577</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>July 11, 2012</results_first_submitted>
  <results_first_submitted_qc>July 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2012</results_first_posted>
  <last_update_submitted>August 23, 2012</last_update_submitted>
  <last_update_submitted_qc>August 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American Institute for Voice and Ear Research</investigator_affiliation>
    <investigator_full_name>Robert T. Sataloff, MD</investigator_full_name>
    <investigator_title>M.D., D.M.A., FACS</investigator_title>
  </responsible_party>
  <keyword>Gastroesophageal reflux</keyword>
  <keyword>Laryngitis</keyword>
  <keyword>Hoarseness</keyword>
  <keyword>Dysphonia</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Laryngopharyngeal Reflux</mesh_term>
    <mesh_term>Laryngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Inadequate recruitment during this study; therefore, the study was terminated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>Placebo for Lansoprazole twice daily</description>
        </group>
        <group group_id="P2">
          <title>Lansoprazole</title>
          <description>Lansoprazole 30 mg twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>Placebo for Lansoprazole twice daily</description>
        </group>
        <group group_id="B2">
          <title>Lansoprazole</title>
          <description>Lansoprazole 30 mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" spread="11.56"/>
                    <measurement group_id="B2" value="40.1" spread="17.33"/>
                    <measurement group_id="B3" value="37.5" spread="15.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Improvement or Resolution of Arytenoid Erythema</title>
        <description>Improvement was measured by score on an arytenoid erythema grading scale assigned by member of research staff and independent observers at 6 weeks</description>
        <time_frame>6 weeks</time_frame>
        <population>No results to report; Study was terminated</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>Placebo for Lansoprazole twice daily</description>
          </group>
          <group group_id="O2">
            <title>Lansoprazole</title>
            <description>Lansoprazole 30 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement or Resolution of Arytenoid Erythema</title>
          <description>Improvement was measured by score on an arytenoid erythema grading scale assigned by member of research staff and independent observers at 6 weeks</description>
          <population>No results to report; Study was terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>Placebo for Lansoprazole twice daily</description>
        </group>
        <group group_id="E2">
          <title>Lansoprazole</title>
          <description>Lansoprazole 30 mg twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated due to inadequate subject recruitment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert T. Sataloff, M.D., D.M.A., FACS</name_or_title>
      <organization>Philadelphia ENT Associates</organization>
      <phone>215-545-3322</phone>
      <email>rtsataloff@phillyent.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

